- SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access — Recruiting • Oncology • NCT02834884.
- What is being tested: SPECTA is a standardized biobank platform collecting high-quality annotated biological samples, imaging data, operative records, and patient-reported outcomes from cancer patients to enable biomarker discovery and support translational research across multiple cancer types.
- Patient eligibility overview: The platform recruits cancer patients across various tumour types and disease stages, with structured collection of clinicopathological data, environmental assessments, and validated questionnaires to create a comprehensive, quality-assured research resource.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
- * Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.